Page 195 - 80_01
P. 195
Propuesta
biotecnológica
para
el
tratamiento
del
cáncer
de
cérvix
uterino…
2.
Soto--Vázquez,
R.;
Análisis
epistemiológico
de
la
construcción
conceptual
a
partir
del
modelo
de
curvas
para
un
desarrollo
biotecnológico;
Tesis
de
Maestría,
Universidad
Nacional
Autónoma
de
México;
México
D.F.,
2000.
3.
Patente
presentada:
Rangel--Corona,
R.,
et
al.
Composición
de
un
producto
antineoplásico
e
inmunorregulador
y
su
uso
para
el
tratamiento
de
cáncer
cérvico
uterino.
Expediente:
MX/a/2008/008681.
4.
Corona,
T.;
Rangel,
R.;
Hernández,
M.;
Baeza,
I.;
Ibánez,
M.;
Weiss,
B.
Characterization
of
cationic
liposomes
having
IL--2
expressed
on
their
external
surface,
and
their
affinity
to
cervical
cáncer
cells
expressing
the
IL--2
receptor.
Journal
of
Drug
Targeting,
17(7),
496--501
(2009).
5.
Mule,
J.;
Shu,
S.;
Rosenberg,
S.
The
anti--tumor
efficacy
of
lymphokine--activated
killer
cells
and
recombinant
interleukin
2
in
vivo.
Journal
of
Immunology
135,
646--652
(1985).
6.
Kondapaneni,
M.;
McGregor,
J.;
Salvemini,
D.;
Laubach,
V.;
Samlowski,
W.
Inducible
nitric
oxide
synthase
(iNOS)
is
not
required
for
IL--2--induced
hypotension
and
vascular
leak
syndrome
in
mice.
Journal
of
Immunotherapy
31,
325--333
(2008).
7.
Bao,
A.;
Phillips,
W.;
Goins,
B.;
Zheng,
X.;
Sabour,
S.;
Natarajan,
M.
F.;
Woolley,
F.;
Zavaleta,
C.;
Otto,
R.
Potential
use
of
drug
carried--liposomes
for
cancer
therapy
via
direct
intratumoral
injection.
International
Journal
of
Pharmacy
316,
162--169
(2006).
8.
Kepczynski,
M.;
Nawalany,
K.;
Kumorek,
M.;
Kobierska,
A.;
Jachimska,
B.;
Nowakowska,
M.
Which
physical
and
structural
factors
of
liposome
carriers
control
their
drug--loading
efficiency?.
Chemical
Physical
Lipids
155,
7--15
(2008).
9.
Pellequer,
Y.;
Ollivon,
M.;
Barratt,
G.
Formulation
of
liposomes
associated
with
recombinant
interleukin--2:
effect
on
interleukin--2
activity.
Biomedicine
&
Pharmacotherapy
58,
162–167
(2004).
10.
Fahr,
A.;
Van
Hoogevest,
P.;
May,
S.;
Bergstrand,
N.;
Leigh,
M.
Transfer
of
lipophilic
drugs
between
liposomal
membranes
and
biological
interfaces:
Consequences
for
drug
delivery.
European
Journal
of
Pharmaceutical
Sciences
26,
251–265
(2005).
11.
Konigsberg,
P.;
Godtel,
R.;
Kissel,
T.;
Richer,
L.
The
development
of
IL--2
conjugated
liposomes
for
therapeutic
purposes.
Biochemical
and
Biophysics
Acta
1370,
243--251
(1998).
12.
Bien,
E.;
Balcerska,
A.
Serum
soluble
interleukin
2
receptor
alpha
in
human
cancer
of
adults
and
children:
a
review.
Biomarkers
13,
1--26
(2008).
13.
Rangel--Corona,
R.;
Rodríguez--Cruz,
L.;
Flores--Flores,
G.;
Gómez--Ruiz,
C.;
Soto--Cruz,
I.;
Mendoza--
Rincon,
J.F.;
Weiss--Steider,
B.
Differential
expression
of
the
two
components
of
the
Interleukin--2
receptor
in
cervical
cancer
cells.
Monduzzie
Editors
3,
1239--1243
(1998).
14.
Rangel--Corona,
R.;
Corona--Ortega,
T.;
del
Río--Ortiz,
I.;
Nieves--Ramírez,
M.;
Morán--Bañuelos,
H.;
González--Tenorio,
O.;
Cáceres--Cortés,
J.;
Weiss--Steider,
B.
Cationic
liposomes
bearing
IL--2
on
their
external
surface
induced
mice
leukocytes
to
kill
human
cervical
cancer
cells
in
vitro,
and
significantly
reduced
tumor
burden
in
immunodepressed
mice.
Journal
of
Drug
Targeting
19(2),
79–85
(2011).
15.
Ibáñez,
M.;
Gariglio,
P.;
Chávez,
P.;
Santiago,
R.;
Wong,
C.;
Baeza,
I.
Spermidine--condensed
DNA
and
cone--shaped
lipids
improve
delivery
and
expression
of
exogenous
DNA
transfer
by
liposomes.
Biochemical
Cellular
Biology
74,
633--643
(1996).
16.
Acosta
Gutiérrez,
J.;
Juárez
López,
R.;
Velasco
Lomas,
I.;
Gil
Alegre,
M.
E.;
Rangel--Corona,
R.;
Weiss--Steider,
B.;
Soto
Vázquez,
R.;
Corona
Ortega,
T.
Estudios
de
estabilidad
farmacéutica
de
un
sistema
constituido
por
un
producto
antineoplásico
e
inmunoregulador
para
el
tratamiento
del
cáncer
cérvico
uterino.
Revista
Portuguesa
de
Farmácia,
P--B
21
(2011).
17.
International
Conference
on
Harmonisation
of
technical
requirements
for
registration
of
pharmaceuticals
for
human
use.
ICH
Q1B.
Stability
testing:
Photostability
testing
of
new
drug
substances
and
products
ICH
harmonised
tripartite
guideline.
1996
18.
International
Conference
on
Harmonisation
of
technical
requirements
for
registration
of
pharmaceuticals
for
human
use.
ICH
Q1A(R2)
Stability
testing
of
new
drug
substances
and
products.
2003.
191
